Patents by Inventor Donglu Zhang

Donglu Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF
    Publication number: 20230330249
    Abstract: The subject matter described herein is directed to antibody-CIDE conjugates (Ab-CIDEs) that target BRM for degradation, to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where BRM degradation is beneficial.
    Type: Application
    Filed: January 19, 2023
    Publication date: October 19, 2023
    Applicant: Genentech, Inc.
    Inventors: Peter Scott DRAGOVICH, Summer A. BAKER DOCKREY, Thomas Harden PILLOW, Donglu ZHANG
  • Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
    Patent number: 11576979
    Abstract: The invention relates generally to pyrrolobenzodiazepine monomer and dimer prodrugs having a glutathione-activated disulfide prodrug moiety, a DT-diaphorase-activated quinone prodrug moiety or a reactive oxygen species-activated aryl boronic acid or aryl boronic ester prodrug moiety. The invention further relates to pyrrolobenzodiazepine prodrug dimer-antibody conjugates.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: February 14, 2023
    Assignee: Genentech, Inc.
    Inventors: Peter Dragovich, Zhonghua Pei, Thomas Pillow, Jack Sadowsky, Vishal Verma, Donglu Zhang
  • PYRROLOBENZODIAZEPINE PRODRUGS AND ANTIBODY CONJUGATES THEREOF
    Publication number: 20200085965
    Abstract: The invention relates generally to pyrrolobenzodiazepine monomer and dimer prodrugs having a glutathione-activated disulfide prodrug moiety, a DT-diaphorase-activated quinone prodrug moiety or a reactive oxygen species-activated aryl boronic acid or aryl boronic ester prodrug moiety. The invention further relates to pyrrolobenzodiazepine prodrug dimer-antibody conjugates.
    Type: Application
    Filed: November 20, 2019
    Publication date: March 19, 2020
    Applicant: GENENTECH, INC.
    Inventors: Peter DRAGOVICH, Zhonghua PEI, Thomas PILLOW, Jack SADOWSKY, Vishal VERMA, Donglu ZHANG
  • Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
    Patent number: 10532108
    Abstract: The invention relates generally to pyrrolobenzodiazepine monomer and dimer prodrugs having a glutathione-activated disulfide prodrug moiety, a DT-diaphorase-activated quinone prodrug moiety or a reactive oxygen species-activated aryl boronic acid or aryl boronic ester prodrug moiety. The invention further relates to pyrrolobenzodiazepine prodrug dimer-antibody conjugates.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: January 14, 2020
    Assignee: GENENTECH, INC.
    Inventors: Peter Dragovich, Zhonghua Pei, Thomas Pillow, Jack Sadowsky, Vishal Verma, Donglu Zhang
  • PYRROLOBENZODIAZEPINE PRODRUGS AND ANTIBODY CONJUGATES THEREOF
    Publication number: 20190175749
    Abstract: The invention relates generally to pyrrolobenzodiazepine monomer and dimer prodrugs having a glutathione-activated disulfide prodrug moiety, a DT-diaphorase-activated quinone prodrug moiety or a reactive oxygen species-activated aryl boronic acid or aryl boronic ester prodrug moiety. The invention further relates to pyrrolobenzodiazepine prodrug dimer-antibody conjugates.
    Type: Application
    Filed: February 8, 2019
    Publication date: June 13, 2019
    Applicant: GENENTECH, INC.
    Inventors: Peter DRAGOVICH, Zhonghua PEI, Thomas PILLOW, Jack SADOWSKY, Vishal VERMA, Donglu ZHANG
  • Mass defect filter
    Patent number: 7381568
    Abstract: A method for detecting and identifying metabolites in biological samples includes subjecting the samples to high resolution mass spectrometry (MS) analysis to detect ions of the molecular species. Mass defect values for the detected ions are determined. The method also includes specifying a predetermined range for mass defect values. Detected ions having mass defect values falling outside the specified range are discarded and those with mass defect values falling within the predetermined range are retained. Species of interest are determined from the retained values. The species of interest include drug metabolites or impurities and/or degradants of a known pharmaceutical sample.
    Type: Grant
    Filed: June 2, 2004
    Date of Patent: June 3, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Haiying Zhang, Kenneth L. Ray, Donglu Zhang
  • Mass defect filter
    Publication number: 20050272168
    Abstract: A method for detecting and identifying metabolites in biological samples includes subjecting the samples to high resolution mass spectrometry (MS) analysis to detect ions of the molecular species. Mass defect values for the detected ions are determined. The method also includes specifying a predetermined range for mass defect values. Detected ions having mass defect values falling outside the specified range are discarded and those with mass defect values falling within the predetermined range are retained. Species of interest are determined from the retained values. The species of interest include drug metabolites or impurities and/or degradants of a known pharmaceutical sample.
    Type: Application
    Filed: June 2, 2004
    Publication date: December 8, 2005
    Inventors: Haiying Zhang, Kenneth Ray, Donglu Zhang